Related Experiment Video
Updated: Mar 3, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Results of the STOP-Hypertension-2 Trial
1a Clinical Hypertension Research, Department of Public Health and Social Services, University of Uppsala, 751 25 Uppsala, Sweden.
Insights
Newer blood pressure drugs, including ACE inhibitors and calcium antagonists, showed similar cardiovascular benefits as older treatments in elderly patients. Lowering blood pressure effectively is key for preventing heart events in older adults.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Elderly hypertensive patients require effective treatments to reduce cardiovascular risks.
- Established therapies like beta-blockers and diuretics are common, but newer options like ACE inhibitors and calcium antagonists are also widely used.
Purpose of the Study:
- To compare the cardiovascular mortality and morbidity of newer antihypertensive therapies (ACE inhibitors, calcium antagonists) versus established therapies (beta-blockers, diuretics) in elderly hypertensive patients.
- To evaluate the safety and tolerability of these different treatment groups.
Main Methods:
- The second Swedish Trial in Old patients with Hypertension (STOP-Hypertension-2) randomized 6614 elderly hypertensive patients.
- Patients received conventional treatment, ACE inhibitors, or calcium antagonists for a mean of 5 years.
- Primary endpoint: fatal stroke, myocardial infarction, or other fatal cardiovascular disease. Secondary endpoints included fatal/non-fatal stroke/myocardial infarction and other cardiovascular mortality.
Main Results:
- All three treatment groups achieved similar reductions in supine systolic blood pressure.
- No significant differences in the risk of major cardiovascular events were observed between newer and conventional therapies.
- All antihypertensive regimens were well tolerated by the elderly participants.
Conclusions:
- Blood pressure reduction is beneficial for elderly hypertensive patients, regardless of the specific therapy used.
- The findings support current guidelines emphasizing achieved blood pressure reduction for cardiovascular event prevention.
- Newer antihypertensive agents demonstrate comparable efficacy and safety to established treatments in this population.
Abstract:
The second Swedish Trial in Old patients with Hypertension (STOP-Hypertension-2) was conducted to compare the effects of 'newer( antihypertensive therapies (angiotensin converting enzyme [ACE] inhibitors and calcium antagonists) and established therapies (beta-blockers and diuretics) on cardiovascular mortality and morbidity in elderly hypertensive patients. A total of 6614 patients were randomized to receive conventional treatment, ACE inhibitors or calcium antagonists, and followed for a mean of 5 years. The primary endpoint was a combination of fatal stroke, fatal myocardial infarction and other fatal cardiovascular disease; secondary endpoints were a combination of fatal or non-fatal stroke or myocardial infarction, and other cardiovascular mortality. The three treatments produced similar reductions in supine systolic blood pressure. There were no significant differences in the risk of cardiovascular events between patients receiving conventional therapy and those receiving newer therapies. All three treatments were well tolerated. The STOP-Hypertension-2 results thus add to the extensive literature showing the benefits of blood pressure reduction in elderly hypertensive patients. Moreover, they are consistent with current management guidelines which emphasise the importance of the achieved blood pressure reduction in the prevention of cardiovascular events.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension and Regulation of Blood Pressure
Hypertension I: Introduction
Hypertension V: Nursing Management

